A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

NCT06073847 · clinicaltrials.gov ↗

RECRUITING

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Fedratinib

Sponsor

Bristol-Myers Squibb